{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:11:28Z","timestamp":1785813088696,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"DOI":"10.7759\/cureus.40124","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T13:25:53Z","timestamp":1686230753000},"source":"Crossref","is-referenced-by-count":1,"title":["Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Patients Aged Over 60 Years"],"prefix":"10.7759","author":[{"given":"Dipabali","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kokab Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roba","family":"Al Shouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Allakky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asila A","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aujala Irfan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baraa","family":"Abuzainah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Dheeraj","family":"Gutlapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25046","article-title":"Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine","volume":"9","author":"Cabez\u00f3n M","year":"2018","unstructured":"Cabez\u00f3n M, Bargay J, Xicoy B, et al.. Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. Oncotarget. 2018, 9:19342-55. 10.18632\/oncotarget.25046","journal-title":"Oncotarget"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey E","year":"2022","unstructured":"Estey E, Hasserjian RP, D\u00f6hner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2022, 139:323-32. 10.1182\/blood.2021011304","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber DA","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et al.. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016, 127:2391-405. 10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04465-4","article-title":"Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial","volume":"100","author":"Heuser M","year":"2021","unstructured":"Heuser M, Smith BD, Fiedler W, et al.. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Ann Hematol. 2021, 100:1181-94. 10.1007\/s00277-021-04465-4","journal-title":"Ann Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25769","article-title":"Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy","volume":"95","author":"Montalban-Bravo G","year":"2020","unstructured":"Montalban-Bravo G, Kanagal-Shamanna R, Class CA, et al.. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020, 95:612-22. 10.1002\/ajh.25769","journal-title":"Am J Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04513-z","article-title":"Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique","volume":"100","author":"Owattanapanich W","year":"2021","unstructured":"Owattanapanich W, Herzig J, Jahn N, et al.. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique. Ann Hematol. 2021, 100:1983-93. 10.1007\/s00277-021-04513-z","journal-title":"Ann Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/genes11080845","article-title":"AML with myelodysplasia-related changes: development, challenges, and treatment advances","volume":"11","author":"Koenig KL","year":"2020","unstructured":"Koenig KL, Sahasrabudhe KD, Sigmund AM, Bhatnagar B. AML with myelodysplasia-related changes: development, challenges, and treatment advances. Genes (Basel). 2020, 11:845. 10.3390\/genes11080845","journal-title":"Genes (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31398","article-title":"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"124","author":"Assi R","year":"2018","unstructured":"Assi R, Kantarjian HM, Kadia TM, et al.. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018, 124:2758-65. 10.1002\/cncr.31398","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04467-2","article-title":"Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: translational analysis of the HOVON103 AML\/SAKK30\/10 Swiss trial cohort","volume":"100","author":"Brune MM","year":"2021","unstructured":"Brune MM, St\u00fcssi G, Lundberg P, et al.. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: translational analysis of the HOVON103 AML\/SAKK30\/10 Swiss trial cohort. Ann Hematol. 2021, 100:1169-79. 10.1007\/s00277-021-04467-2","journal-title":"Ann Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000162","article-title":"Old dogs, new tricks: revisiting immune modulatory approaches for myelodysplastic syndromes","volume":"2","author":"G\u00f6tze KS","year":"2018","unstructured":"G\u00f6tze KS, Platzbecker U. Old dogs, new tricks: revisiting immune modulatory approaches for myelodysplastic syndromes. Hemasphere. 2018, 2:e162. 10.1097\/HS9.0000000000000162","journal-title":"Hemasphere"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00361-8","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program","volume":"10","author":"Guolo F","year":"2020","unstructured":"Guolo F, Fianchi L, Minetto P, et al.. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J. 2020, 10:96. 10.1038\/s41408-020-00361-8","journal-title":"Blood Cancer J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018021980","article-title":"Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity","volume":"2","author":"Eapen M","year":"2018","unstructured":"Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, Horowitz MM, Deeg HJ. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018, 2:2095-103. 10.1182\/bloodadvances.2018021980","journal-title":"Blood Adv"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al.. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022, 140:1200-28. 10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.166173","article-title":"Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes","volume":"102","author":"Meggendorfer M","year":"2017","unstructured":"Meggendorfer M, Haferlach C, Kern W, Haferlach T. Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes. Haematologica. 2017, 102:1502-10. 10.3324\/haematol.2017.166173","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5421","article-title":"Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency","volume":"12","author":"Zhao D","year":"2023","unstructured":"Zhao D, Eladl E, Zarif M, et al.. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency. Cancer Med. 2023, 12:6511-22. 10.1002\/cam4.5421","journal-title":"Cancer Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138478","article-title":"p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia","volume":"6","author":"Man N","year":"2021","unstructured":"Man N, Mas G, Karl DL, et al.. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia. JCI Insight. 2021, 6:e138478. 10.1172\/jci.insight.138478","journal-title":"JCI Insight"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-21-X2","article-title":"Targeting CD47\/SIRP\u03b1 in acute myeloid leukemia and myelodysplastic syndrome: preclinical and clinical developments of magrolimab","volume":"4","author":"Haddad F","year":"2021","unstructured":"Haddad F, Daver N. Targeting CD47\/SIRP\u03b1 in acute myeloid leukemia and myelodysplastic syndrome: preclinical and clinical developments of magrolimab. J Immunother Precis Oncol. 2021, 4:67-71. 10.36401\/JIPO-21-X2","journal-title":"J Immunother Precis Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.187278","article-title":"Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome","volume":"104","author":"Stomper J","year":"2019","unstructured":"Stomper J, Ihorst G, Suciu S, et al.. Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome. Haematologica. 2019, 104:59-69. 10.3324\/haematol.2017.187278","journal-title":"Haematologica"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002929","article-title":"Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies","volume":"5","author":"Patel AA","year":"2021","unstructured":"Patel AA, Cahill K, Saygin C, Odenike O. Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021, 5:2264-71. 10.1182\/bloodadvances.2020002929","journal-title":"Blood Adv"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2011.04.011","article-title":"Failure of hypomethylating agent-based therapy in myelodysplastic syndromes","volume":"38","author":"Kadia TM","year":"2011","unstructured":"Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol. 2011, 38:682-92. 10.1053\/j.seminoncol.2011.04.011","journal-title":"Semin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.007","article-title":"A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): results of CALGB 100801 (Alliance)","volume":"25","author":"Vij R","year":"2019","unstructured":"Vij R, Le-Rademacher J, Laumann K, et al.. A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): results of CALGB 100801 (Alliance). Biol Blood Marrow Transplant. 2019, 25:1984-92. 10.1016\/j.bbmt.2019.06.007","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.207118","article-title":"A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure","volume":"104","author":"S\u00e9bert M","year":"2019","unstructured":"S\u00e9bert M, Renneville A, Bally C, et al.. A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica. 2019, 104:1565-71. 10.3324\/haematol.2018.207118","journal-title":"Haematologica"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts","volume":"31","author":"Garcia-Manero G","year":"2017","unstructured":"Garcia-Manero G, Sekeres MA, Egyed M, et al.. A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts. Leukemia. 2017, 31:2799-806. 10.1038\/leu.2017.159","journal-title":"Leukemia"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2019.01.002","article-title":"Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged \u226570 years","volume":"12","author":"Lachowiez C","year":"2019","unstructured":"Lachowiez C, Cook RJ, Hayes-Lattin B, et al.. Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged \u226570 years. Hematol Oncol Stem Cell Ther. 2019, 12:105-9. 10.1016\/j.hemonc.2019.01.002","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001818","article-title":"Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia\/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Saberian C","year":"2021","unstructured":"Saberian C, Abdel-Wahab N, Abudayyeh A, et al.. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia\/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2021, 9:001818. 10.1136\/jitc-2020-001818","journal-title":"J Immunother Cancer"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.168716","article-title":"Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation","volume":"103","author":"Schmid C","year":"2018","unstructured":"Schmid C, de Wreede LC, van Biezen A, et al.. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Haematologica. 2018, 103:237-45. 10.3324\/haematol.2017.168716","journal-title":"Haematologica"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2019.09.002","article-title":"Comparative effectiveness of busulfan\/cyclophosphamide versus busulfan\/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome","volume":"13","author":"Patel SS","year":"2020","unstructured":"Patel SS, Rybicki L, Pohlman B, et al.. Comparative effectiveness of busulfan\/cyclophosphamide versus busulfan\/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol Stem Cell Ther. 2020, 13:160-5. 10.1016\/j.hemonc.2019.09.002","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005397","article-title":"Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome","volume":"136","author":"Myllym\u00e4ki M","year":"2020","unstructured":"Myllym\u00e4ki M, Redd R, Reilly CR, et al.. Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood. 2020, 136:3070-81. 10.1182\/blood.2020005397","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/125438-secondary-acute-myeloid-leukemia-in-myelodysplastic-syndrome-patients-aged-over-60-years","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:57Z","timestamp":1707508857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/125438-secondary-acute-myeloid-leukemia-in-myelodysplastic-syndrome-patients-aged-over-60-years"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.40124","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}